Efficacy and safety of Tripterygium glycosides as an add-on treatment in adults with chronic urticaria : a systematic review and meta-analysis
CONTEXT: Tripterygium glycosides (TG), a traditional Chinese medicine, has been used to treat chronic urticaria (CU) in China, and the evidence of TG for CU needs to be updated thoroughly.
OBJECTIVE: To systematically evaluate the efficacy and safety of TG combined with H1-antihistamine (H1-AH) in adults with CU.
METHODS: Eligible randomized controlled trials were searched in eight databases until May 31, 2022, including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science. The search terms included urticaria, Tripterygium, Lei Gong Teng, and Leigongteng. Rev Man 5.3 and Stata 12.0 were used for statistical analysis.
RESULTS: A total of 27 studies with 2788 patients were included. The pooled results showed that TG plus H1-AH was superior to H1-AH alone in cure rate (RR = 1.37, 95% CI = 1.15 to 1.63, p = 0.0003), total efficacy rate (RR = 1.40, 95% CI = 1.30 to 1.50, p < 0.00001), pruritus (MD = -0.32, 95% CI = -0.54 to -0.11, p = 0.003), wheal number (MD = -0.31, 95% CI = -0.55 to -0.07, p = 0.01), wheal size (MD = -0.32, 95% CI = -0.46 to -0.19, p < 0.00001), and the serum level of immunoglobulin E (SMD = -1.39, 95% CI = -2.42 to -0.36, p = 0.008). Moreover, adverse events between two groups were mild, and their incidences were not significantly different.
CONCLUSIONS: The combination of TG and H1-AH is a promising and safe treatment for adults with refractory CU. Further high-quality studies are needed to confirm the evidence.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:61 |
---|---|
Enthalten in: |
Pharmaceutical biology - 61(2023), 1 vom: 01. Dez., Seite 324-336 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Ming [VerfasserIn] |
---|
Links: |
---|
Themen: |
Adverse event |
---|
Anmerkungen: |
Date Completed 26.01.2023 Date Revised 07.09.2023 published: Print Citation Status MEDLINE |
---|
doi: |
10.1080/13880209.2023.2169468 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM352055189 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM352055189 | ||
003 | DE-627 | ||
005 | 20231226052839.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/13880209.2023.2169468 |2 doi | |
028 | 5 | 2 | |a pubmed24n1173.xml |
035 | |a (DE-627)NLM352055189 | ||
035 | |a (NLM)36694954 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Ming |e verfasserin |4 aut | |
245 | 1 | 0 | |a Efficacy and safety of Tripterygium glycosides as an add-on treatment in adults with chronic urticaria |b a systematic review and meta-analysis |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 26.01.2023 | ||
500 | |a Date Revised 07.09.2023 | ||
500 | |a published: Print | ||
500 | |a Citation Status MEDLINE | ||
520 | |a CONTEXT: Tripterygium glycosides (TG), a traditional Chinese medicine, has been used to treat chronic urticaria (CU) in China, and the evidence of TG for CU needs to be updated thoroughly | ||
520 | |a OBJECTIVE: To systematically evaluate the efficacy and safety of TG combined with H1-antihistamine (H1-AH) in adults with CU | ||
520 | |a METHODS: Eligible randomized controlled trials were searched in eight databases until May 31, 2022, including CNKI, WanFang, VIP, SinoMed, PubMed, Cochrane Library, Embase, and Web of Science. The search terms included urticaria, Tripterygium, Lei Gong Teng, and Leigongteng. Rev Man 5.3 and Stata 12.0 were used for statistical analysis | ||
520 | |a RESULTS: A total of 27 studies with 2788 patients were included. The pooled results showed that TG plus H1-AH was superior to H1-AH alone in cure rate (RR = 1.37, 95% CI = 1.15 to 1.63, p = 0.0003), total efficacy rate (RR = 1.40, 95% CI = 1.30 to 1.50, p < 0.00001), pruritus (MD = -0.32, 95% CI = -0.54 to -0.11, p = 0.003), wheal number (MD = -0.31, 95% CI = -0.55 to -0.07, p = 0.01), wheal size (MD = -0.32, 95% CI = -0.46 to -0.19, p < 0.00001), and the serum level of immunoglobulin E (SMD = -1.39, 95% CI = -2.42 to -0.36, p = 0.008). Moreover, adverse events between two groups were mild, and their incidences were not significantly different | ||
520 | |a CONCLUSIONS: The combination of TG and H1-AH is a promising and safe treatment for adults with refractory CU. Further high-quality studies are needed to confirm the evidence | ||
650 | 4 | |a Meta-Analysis | |
650 | 4 | |a Systematic Review | |
650 | 4 | |a Journal Article | |
650 | 4 | |a Randomized controlled trials | |
650 | 4 | |a adverse event | |
650 | 4 | |a effectiveness | |
650 | 4 | |a traditional Chinese medicine | |
650 | 7 | |a Glycosides |2 NLM | |
650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
700 | 1 | |a Li, Yan |e verfasserin |4 aut | |
700 | 1 | |a Xiang, Lujing |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Pharmaceutical biology |d 1997 |g 61(2023), 1 vom: 01. Dez., Seite 324-336 |w (DE-627)NLM097504416 |x 1744-5116 |7 nnns |
773 | 1 | 8 | |g volume:61 |g year:2023 |g number:1 |g day:01 |g month:12 |g pages:324-336 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/13880209.2023.2169468 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 61 |j 2023 |e 1 |b 01 |c 12 |h 324-336 |